Mental Health Research Accelerator Act of 2025

HR 2085 creates a 25% tax credit for businesses and tax-exempt entities (like hospitals or nonprofits) conducting translational research on neurodegenerative diseases and psychiatric conditions. The credit covers 25% of qualifying research expenses, with annual funding limits of $1 billion in 2026, $2 billion annually from 2027-2030, and $1 billion in 2031. Funds are allocated based on scientific merit, requiring projects to cover all research phases, prioritize new therapies for mental/neurological disorders, and encourage public-private partnerships. The credit expires after 2035 and cannot be used to offset deductions for the same expenses.